QBiotics

Head and neck cancer
#Head and neck cancer #Oncology #Phase II trial #QBiotics

Phase II data show durable responses in head and neck cancer

QBiotics has announced positive results from its Phase II QB46C-H08 trial, with tigilanol tiglate achieving a 78% Objective Response Rate (ORR) in patients with head and neck solid malignancies who were refractory to standard of care.   The company says the result, based on 14 responses across 18… Read More

#Cancer Research #News

Blushwood tree
#Head and neck cancer #Oncology #Plant-based #QBiotics #Solid tumours #The Institute of Cancer Research

Could a molecule from a rainforest tree treat solid tumour cancers?

Scientists at The Institute of Cancer Research, London, are collaborating with life sciences company QBiotics to understand the molecular and cellular mechanisms of a potential new cancer drug.  The collaborative team will study the effects of tigilanol tiglate – a naturally occurring small molecule derived from the… Read More

#Cancer Research #Editor's Choice #News